top of page

A Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

We are working with Axial and three other sites to assess the safety, tolerability and efficacy of a pharmaceutical therapy called AB-2004.

​

Phase 1b/2a of the study explored whether AB-2004’s ability to reduce the availability of certain gut bacteria, such as p-cresol, can improve gastrointestinal symptoms and some related behavioural challenges in autistic individuals.

​

Phase 2b of the study is now underway, investigating whether treatment with AB-2004 can improve irritability in autistic children. Eligible participants will be randomly assigned to receive AB-2004 or a placebo.

​

You can read more on the study's website. 

Recruitment

To be eligible, participants must be:

  • Male, aged 12 - <18 years old.

  • Have an autism diagnosis

  • Experience irritability

  • Have no medical conditions as described in the exclusion criteria

​

This study is currently OPEN. Register your interest below. 

​

​

Initial findings are promising and can be read about here.

 

​

Initial findings are promising and can be read about here.

​

Results

bottom of page